What is GH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 21.87B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GH?

P/E (TTM) is n/a and 52-week range is $61.00 to $191.05 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GH?

The company profile lists revenue (TTM) near $1.18B, net income (TTM) near $-45.26B, EPS (TTM) near $-3.50 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Guardant Health Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Palo Alto, California, US, 132.6M shares outstanding, ISIN US40131M1099 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Guardant Health Inc

$GH

Health Care · Health Care Providers & Services

IR Run Scenarios

$162.99

+0.56%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,490

Website

guardanthealth.com/

IPO

2018-10-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)